Dr. Kalota is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6325 E Tanque Verde rd
Tucson, AZ 85715Phone+1 520-795-5830Fax+1 520-885-4469
Education & Training
University of California (San Diego) Medical CenterResidency, Urology, 1988 - 1992- University of California (San Diego) Medical CenterResidency, Surgery, 1986 - 1988
Howard University College of MedicineClass of 1986
Certifications & Licensure
CA State Medical License 1988 - Present
AZ State Medical License 1992 - 2025
TX State Medical License 2023 - 2023- American Board of Urology Urology
- American Board of Urology Female Pelvic Medicine and Reconstructive Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
Clinical Trials
- Study of Macroplastique Safety and Effectiveness in the Treatment of Female Stress Urinary Incontinence Start of enrollment: 2008 Jan 01
- Solace Stress Urinary inContinence Control Efficacy and Safety Study Start of enrollment: 2014 Aug 11
- LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve Start of enrollment: 2021 Apr 22
Roles: Contact
Publications & Presentations
PubMed
- 9 citationsInfantile Hypertrophic Pyloric Stenosis and Hydronephrosis: Is there an Association?Mohamed Bidair, Susan Kalota, George W. Kaplan
The Journal of Urology. 1993-07-01 - 11 citationsFexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement.Neal D. Shore, Ronald F. Tutrone, Mitchell Efros, Mohamed Bidair, Barton Wachs
World Journal of Urology. 2018-01-29 - 2 citationsProspective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results.Neal D. Shore, Steven A. Kaplan, Ronald F. Tutrone, Richard Levin, James Bailen
World Journal of Urology. 2020-02-22
Press Mentions
Nymox Provides Update on Regulatory Filing ActivitiesNovember 16th, 2020- NYMOX Provides Current Update on Key Company DevelopmentsJuly 28th, 2020
Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco May 20May 2nd, 2018- Join now to see all
Professional Memberships
- Member
Other Languages
- French, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
